AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 162 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,917 | -12.6% | 1,532 | 0.0% | 0.00% | -25.0% |
| Q2 2023 | $43,386 | +23.5% | 1,532 | +0.1% | 0.00% | +33.3% |
| Q1 2023 | $35,144 | -18.3% | 1,530 | -0.1% | 0.00% | -25.0% |
| Q4 2022 | $43,019 | +0.0% | 1,532 | +0.1% | 0.00% | 0.0% |
| Q3 2022 | $43,000 | +26.5% | 1,530 | 0.0% | 0.00% | +33.3% |
| Q2 2022 | $34,000 | -24.4% | 1,530 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $45,000 | -10.0% | 1,530 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $50,000 | -29.6% | 1,530 | 0.0% | 0.00% | -40.0% |
| Q3 2021 | $71,000 | -15.5% | 1,530 | 0.0% | 0.01% | -16.7% |
| Q2 2021 | $84,000 | +6.3% | 1,530 | 0.0% | 0.01% | 0.0% |
| Q1 2021 | $79,000 | +19.7% | 1,530 | 0.0% | 0.01% | +20.0% |
| Q4 2020 | $66,000 | +112.9% | 1,530 | +73.9% | 0.01% | +66.7% |
| Q3 2020 | $31,000 | -34.0% | 880 | 0.0% | 0.00% | -25.0% |
| Q2 2020 | $47,000 | +51.6% | 880 | 0.0% | 0.00% | +33.3% |
| Q1 2020 | $31,000 | – | 880 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |